TD Cowen analyst Marc Frahm has maintained their bullish stance on CRDF stock, giving a Buy rating on April 29.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Marc Frahm’s rating is based on several promising developments in Cardiff Oncology’s ongoing clinical trials. The company has completed enrollment in the CRDF-004 trial, which evaluates the efficacy of onvansertib in combination with other treatments for first-line RAS+ metastatic colorectal cancer. The trial aims to demonstrate a significant improvement in objective response rate (ORR), with interim data already showing promising results.
The interim results indicated a notable ORR benefit in the onvansertib arm compared to the standard of care, and a clear dose response was observed. This success positions Cardiff to potentially pursue accelerated approval strategies similar to those used by other successful trials. With a substantial market opportunity and high unmet medical need, these factors contribute to the optimism reflected in Frahm’s Buy rating.